Canntab; Putting the ‘Medical’ into Medicinal Cannabis
Canntab Therapeutics is bringing pharmaceutical expertise to the cannabis market through the development of its patent-pending Canntab Extended Release (XR) Tablets™. Using proprietary extended release technology previously developed by the company, Canntab is producing a safe, stable and standardized delivery method for cannabis particles (CBD and THC) that is not burdened with the negative effects associated with smoking, edibles or topicals.
The proprietary extended release technology provides lasting effects of 12 to 18 hours, making the Canntab XR Tablets™ an appealing alternative to other intake methods. The XR Tablets™ have also been designed for doses of 2.5 mg, 5.0 mg or 10.0 mg, making dosing and prescribing much more straightforward for the medical community.
Based in Markham, Ontario, the company will be expanding their operations as they move into an independent 10,000 square-foot area within the FV Pharma facility in Cobourg, Ontario. From there, the company will be producing and distributing its products.
Additionally, Canntab has also entered into a licensing agreement with Emblem Corp, a licensed producer (LP), under which Emblem will develop and market Canntab’s XR Tablets™ in Canada.
Beyond Canada, Canntab has entered into a joint venture with Vitacann, a subsidiary of Queensland Bauxite (ASX:QBL) , under which the companies will work towards the approval of sales of Canntab XR Tablets™ in Australia as well as their export to Asia.
Canntab is led by a management team with proven experience in both the pharmaceutical and capital market spaces. The company’s leaders, Jeff Renwick and Richard Goldstein, have been working with their team to develop Canntab’s proprietary technology for almost a decade and have numerous patents for unique drug formulations, making them leaders within the cannabis pharmaceutical space.
The management team is also supported by board members Vitor Fonseca and Sheldon Inwentash, both of which provide extensive insight into financial aspects and business development.
Here you have the opportunity to take advantage on facts and info from QBL. Like the ”QBL on ASX” chapter, who can provide verified facts; here is also regulated on-line stockbrokers suggestion, no games info and a good sum up. Voluntary suspension is requested regarding a significant and strategic acquisition by QBL’s subsidiary Medical Cannabis Limited until next Fridy the 1 of june or before. Contact information to the QBL Investor service, who can reply on questions. https://www.queenslandbauxite.com/ (remember different timezones outside Australia, trade pre-start 7 AM in Sydney, local time, trade opens 10 AM)
Canntab Therapeutics is bringing pharmaceutical expertise to the cannabis market through the development of its patent-pending Canntab Extended Release (XR) Tablets™. Using proprietary extended release technology previously developed by the company, Canntab is producing a safe, stable and standardized delivery method for cannabis particles (CBD and THC) that is not burdened with the negative effects associated with smoking, edibles or topicals.
The proprietary extended release technology provides lasting effects of 12 to 18 hours, making the Canntab XR Tablets™ an appealing alternative to other intake methods. The XR Tablets™ have also been designed for doses of 2.5 mg, 5.0 mg or 10.0 mg, making dosing and prescribing much more straightforward for the medical community.
Based in Markham, Ontario, the company will be expanding their operations as they move into an independent 10,000 square-foot area within the FV Pharma facility in Cobourg, Ontario. From there, the company will be producing and distributing its products.
Additionally, Canntab has also entered into a licensing agreement with Emblem Corp, a licensed producer (LP), under which Emblem will develop and market Canntab’s XR Tablets™ in Canada.
Beyond Canada, Canntab has entered into a joint venture with Vitacann, a subsidiary of Queensland Bauxite (ASX:QBL) , under which the companies will work towards the approval of sales of Canntab XR Tablets™ in Australia as well as their export to Asia.
Canntab is led by a management team with proven experience in both the pharmaceutical and capital market spaces. The company’s leaders, Jeff Renwick and Richard Goldstein, have been working with their team to develop Canntab’s proprietary technology for almost a decade and have numerous patents for unique drug formulations, making them leaders within the cannabis pharmaceutical space.
The management team is also supported by board members Vitor Fonseca and Sheldon Inwentash, both of which provide extensive insight into financial aspects and business development.
Here you have the opportunity to take advantage on facts and info from QBL. Like the ”QBL on ASX” chapter, who can provide verified facts; here is also regulated on-line stockbrokers suggestion, no games info and a good sum up. Voluntary suspension is requested regarding a significant and strategic acquisition by QBL’s subsidiary Medical Cannabis Limited until next Fridy the 1 of june or before. Contact information to the QBL Investor service, who can reply on questions. https://www.queenslandbauxite.com/ (remember different timezones outside Australia, trade pre-start 7 AM in Sydney, local time, trade opens 10 AM)
Robert
